ジカウイルス用ワクチンの世界市場機会分析

◆英語タイトル:MarketVIEW: Zika virus vaccines - Vaccine opportunity assessment
◆商品コード:VACZ60303
◆発行会社(調査会社):VacZine Analytics
◆発行日:2016年2月
◆ページ数:※お問い合わせください。
◆レポート言語:英語
◆レポート形式:PDF, Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆販売価格オプション(消費税別)
Executive Presentation (PDF)GBP3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
PDF+ExcelGBP7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Zika virus (ZIKV) is a member of the Flaviviridae family that includes several mosquito-borne viruses of major clinical importance, including yellow fever virus, Japanese encephalitis virus and dengue virus. Although widely distributed across West and East Africa and Southeast Asia (46 countries/territories since 2007), ZIKV has only recently been identified as a major cause of disease. In most cases, ZIKV usually causes a mild and often asymptomatic illness. However, neonatal microcephaly and Guillain-Barré syndrome (GBS) have recently emerged as possible (but not definitively confirmed) complications of ZIKV infection. For example, in Brazil, an estimated 1.5 million ZIKV cases have occurred since April 2015 and up to November 2015, 1,248 neonatal microcephaly cases have been reported.

ZIKV will likely to spread to other countries in the region that have Aedes mosquitoes. Autochthonous ZIKV transmission is expected to occur in the US whereby the gulf coast region and Florida are most vulnerable. The WHO declared the Zika virus outbreak a global emergency in February 2016. Many private sector companies and government-funded organizations have started work on developing a Zika vaccine due to the significant global public health concern.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Zika virus vaccines across endemic (public + private) and travelers’ markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all key commercial segments. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

*** THIS PRODUCT IS A EXECUTIVE PRESENTATION AND ONE FORECAST MODEL

【レポートの目次】

※レポート紹介PDF⇒http://www.vaczine-analytics.com/VAMV068_TOC_160219.pdf

****This product is composed of one forecast model and a summary presentation
Title page
Contents
Author’s note
Executive summary
Commercial model: key outputs
ZIKV vaccine: predicted global revenues ($m) to 2035
ZIKV vaccine: predicted global revenues (endemic) ($m) to 2035
ZIKV vaccine: predicted global revenues (private) ($m) to 2035
ZIKV vaccine: predicted global revenues (travel) ($m) to 2035
ZIKV vaccine: price sensitivity analysis (endemic/public) – 2027
ZIKV vaccine: key model assumptions
The potential role of a ZIKV vaccine
ZIKV: comparative data to other mosquito borne viruses
ZIKV vaccine: target product profile
ZIKV vaccine: pricing considerations
ZIKV vaccine: estimating potential uptake
ZIKV: target markets for a potential vaccine
Detailed market assumptions: endemic (public)
Detailed market assumptions: endemic (private)
Detailed market assumptions: travellers (private)
Detailed market assumptions: stockpile (public)
Zika virus (ZIKV): disease background and epidemiology
The pathogen
ZIKV: transmission
ZIKV: timeline of geographical spread (1947 – 2016)
Emergence of ZIKV: Yap Island
Emergence of ZIKV: French Polynesia
Emergence of ZIKV: Brazil
Emergence of ZIKV: South (other) and Central America
ZIKV: latest transmission statistics
Countries with current or past evidence of ZIKV infections
Zika virus: economic cost in Latin America
ZIKV: clinical features
ZIKV: symptoms
ZIKV: comparative symptoms with dengue virus and Chikungunya virus
ZIKV: WHO – Global Health Emergency/Strategy
ZIKV associated microcephaly
Microcephaly: latest statistics
Microcephaly rates, by state, Brazil, 2010-2014 and 2015
ZIKV & Guillain-Barré syndrome (GBS)
ZIKV: diagnosis
Algorithm for confirming ZIKV infection
Predicted distribution of Aedes aegypti
Predicted distribution of Aedes albopictus
Occurrence of Aedes albopictus in Europe and the US States
ZIKV: other routes of transmission
ZIKV: treatment and prevention
ZIKV: importation to non-endemic countries
ZIKV: autochtonous transmission in the United States
ZIKV: autochtonous transmission in the European Union
ZIKV: regions susceptible to ZIKV outbreaks
ZIKV vaccines: R&D pipeline – February 2016
Bibliography
About VacZine Analytics
Disclaimer



【レポートのキーワード】

ジカウイルス感染症、ワクチン、治療薬、市場機会、市場規模

★調査レポート[ジカウイルス用ワクチンの世界市場機会分析]販売に関する免責事項
★調査レポート[ジカウイルス用ワクチンの世界市場機会分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆